Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses.
about
Zika Virus: Medical Countermeasure Development ChallengesPredicting Zika virus structural biology: Challenges and opportunities for interventionFeasibility of cross-protective vaccination against flaviviruses of the Japanese encephalitis serocomplexThe essential oil of Brazilian pepper, Schinus terebinthifolia Raddi in larval control of Stegomyia aegypti (Linnaeus, 1762)A Single Amino Acid Substitution in the M Protein Attenuates Japanese Encephalitis Virus in Mammalian HostsAdvanced vaccine candidates for Lassa feverThe yellow fever 17D virus as a platform for new live attenuated vaccinesVaccines in development against West Nile virusJapanese encephalitis: the virus and vaccinesUnderstanding the dengue viruses and progress towards their controlImmunogenicity of seven new recombinant yellow fever viruses 17D expressing fragments of SIVmac239 Gag, Nef, and Vif in Indian rhesus macaquesA Novel Synthetic TLR-4 Agonist Adjuvant Increases the Protective Response to a Clinical-Stage West Nile Virus Vaccine Antigen in Multiple FormulationsDevelopment of a recombinant tetravalent dengue virus vaccine: Immunogenicity and efficacy studies in mice and monkeysThe Potential Use of Wolbachia-Based Mosquito Biocontrol Strategies for Japanese EncephalitisImmune activation alters cellular and humoral responses to yellow fever 17D vaccineStability of yellow fever virus under recombinatory pressure as compared with chikungunya virusCost-Effectiveness of Dengue Vaccination Programs in BrazilDevelopment of replication-competent viral vectors for HIV vaccine delivery.RNA virus reverse genetics and vaccine design.A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice.Dengue vaccines: state of the art.History of vaccinationNew Japanese encephalitis vaccines: alternatives to production in mouse brain.Viscerotropic disease: case definition and guidelines for collection, analysis, and presentation of immunization safety data.Japanese Encephalitis VaccinesPhysicochemical property consensus sequences for functional analysis, design of multivalent antigens and targeted antivirals.The synergistic effect of combined immunization with a DNA vaccine and chimeric yellow fever/dengue virus leads to strong protection against dengue.Plasmid DNA initiates replication of yellow fever vaccine in vitro and elicits virus-specific immune response in miceVaccination strategies against highly pathogenic arenaviruses: the next steps toward clinical trialsBiological and immunological characterization of recombinant Yellow Fever 17D viruses expressing a Trypanosoma cruzi Amastigote Surface Protein-2 CD8+ T cell epitope at two distinct regions of the genomeCurrent trends in West Nile virus vaccine development.Antibody-mediated neutralization of flaviviruses: a reductionist view.Immune responses to an attenuated West Nile virus NS4B-P38G mutant strain.Priming effect of dengue and yellow fever vaccination on the immunogenicity, infectivity, and safety of a tetravalent dengue vaccine in humans.An adjuvanted, tetravalent dengue virus purified inactivated vaccine candidate induces long-lasting and protective antibody responses against dengue challenge in rhesus macaques.Yellow Fever 17DD Vaccine Virus Infection Causes Detectable Changes in Chicken Embryos.Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs.Recombinant Measles AIK-C Vaccine Strain Expressing the prM-E Antigen of Japanese Encephalitis Virus.Simplifying complex sequence information: a PCP-consensus protein binds antibodies against all four Dengue serotypes.Spectrum of disease outcomes in mice infected with YFV-17D
P2860
Q24261184-08D44A0C-0DDB-41ED-A27F-86F08034DF54Q24700044-2A67A209-28D5-4C6B-A324-436B40E1D965Q24737461-459B884B-644F-4513-B133-12A74F302627Q24756401-1F4644F5-D4ED-4AB0-BA1E-10347BFC7633Q26700092-35CFA85C-7D8A-430E-9B78-A24882557187Q26823627-7182504E-91B6-4B20-8A16-BFC4CE6DFE05Q26865102-B07DB617-C4A2-4BCD-AC67-E018F82BBAB6Q26999702-019985B4-F32A-40C0-8364-7B0832C35601Q27010434-3BAB2424-46C6-4193-8D28-26AB154F16D9Q27011587-B18FD6C6-FFB0-47E2-936A-CC8E1300306DQ27319783-9F17EE1C-D3CD-422D-A9B8-9AE12F59080CQ27321020-4A8B2B06-B7FC-4701-9947-F0EA137D8E62Q27491049-6C8C7CFA-34DA-47EB-94FA-D0472BB5F4DBQ28084923-7AB12364-5F60-41F0-B3C5-8C226A752467Q28388716-0333EAB4-C740-437F-A4F3-9C7A054BFC6BQ28741831-A20B2285-F010-4B9B-B403-F36CFDE0D05FQ33636857-BD979560-BEF9-4DBC-8C72-CFA21AC1E20BQ33694226-B3211B7F-C8A5-4DD6-B355-1F9A743DE048Q33963398-A275D4F1-976B-42FE-ADCE-3223ED0F5B9EQ34039347-19BC2567-8E60-468A-96FC-A2BA16D2452BQ34109652-B5A6FC44-49AD-4FFE-A47F-F77CE7C863C2Q34119899-23F42748-4B82-4DB9-B258-E31052AC3AD7Q34173039-A4FDC370-3E6A-40F1-80C4-8BB1FADDA9B1Q34258885-3F127820-7AA8-4938-9782-A00750401FA4Q34466587-FF63BAA4-3364-4D0D-960E-FD022A4C5C55Q34548508-A7E93B62-41D4-4C3E-9593-1945F91CFFD0Q34614953-C15A91B2-E088-44A6-B17E-F19EC610AC9BQ34615061-C909DC3B-46D3-49F0-AB6E-FF3AD07B17FFQ34671806-B3A787F6-A7C2-467F-806B-3F6D7B6DBBCDQ34732681-60928E21-2023-4897-A49F-12B6CBE631CAQ34788758-EB12E9B8-493E-423D-8AEF-5BB1A059F91DQ34999617-5BDBDDD6-08C9-48DE-A3A9-0D8D08F9E0C6Q35042669-413CDB63-0198-4E8F-9A54-7177E96EA29BQ35246126-1B1C0FF8-40CC-4E3B-9743-ECDD9D490437Q35272502-1603D5FF-373E-460F-9BEF-B08D75A00179Q35775796-9A367517-B66B-4B47-871C-7C89AAF8C545Q35814851-672BD96B-68FA-4EB3-B9E0-E2A0941B29E9Q35941078-972F550B-8A5A-4DEA-848F-05EBDFA9F6A5Q36226190-FE3CFB67-2BD9-4621-AA7E-E53EE279E759Q36255083-2CFDEE8B-CA18-42D5-9D6F-95BA2A5CC23D
P2860
Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 October 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Preclinical and clinical devel ...... Japanese encephalitis viruses.
@en
Preclinical and clinical devel ...... Japanese encephalitis viruses.
@nl
type
label
Preclinical and clinical devel ...... Japanese encephalitis viruses.
@en
Preclinical and clinical devel ...... Japanese encephalitis viruses.
@nl
prefLabel
Preclinical and clinical devel ...... Japanese encephalitis viruses.
@en
Preclinical and clinical devel ...... Japanese encephalitis viruses.
@nl
P2093
P50
P921
P1433
P1476
Preclinical and clinical devel ...... Japanese encephalitis viruses.
@en
P2093
Veronique Barban
P304
P356
10.1016/J.VACCINE.2009.09.098
P407
P577
2009-10-04T00:00:00Z